RxDoctor Payments Data

Melissa Burke, MD

Family Medicine · Dade City, FLNPI 1477117877

Payments from drug & device makers

$1,228in general payments, 2019–2025

Across 64 payments — averaging $19.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$297
  • Lilly USA, LLC$260
  • Amgen$227
  • GSK$182
  • Exact Sciences$142
  • Pfizer$59
  • plus $60 from 3 others

What the payments were for

  • Food & beverage$1,228100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,228 in reported general payments places this provider in the 65th percentile of 7,282 family medicine providers in Florida.

See all family medicine providers in Florida

Medicare billing

Part B allowed, 2024
$56,825
Medicare patients
126
Services billed
666

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban22$27,355
OzempicSemaglutide21$21,075
RybelsusSemaglutide14$18,864
JanumetSitagliptin Phos/Metformin Hcl17$12,887
XareltoRivaroxaban11$12,520
Soliqua 100-33Insulin Glargine/Lixisenatide12$10,520
Repatha SyringeEvolocumab11$5,904
Repatha SureclickEvolocumab11$5,873
Atorvastatin Calcium185$1,538
PaxlovidNirmatrelvir/Ritonavir12$1,429
Levothyroxine Sodium152$1,310
Omeprazole82$1,189
Gabapentin54$951
Hydroxyzine Hcl30$642
Losartan Potassium56$626

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$297$39,93835 claims
PfizerEliquis, Paxlovid$59$28,78434 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 7,282 family medicine providers in Florida.

Other family medicine in Dade City

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →